Is there a Bangladeshi generic version of Brigatinib?

Brigatinib/Brigatinib（Brigatinib）There is a Bangladeshi generic version. Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

Brigatinib/Brigatinib (Brigatinib) is an oral anti-tumor drug that is a tyrosine kinase inhibitor (TKI). It is mainly used to treat certain types of non-small cell lung cancer (NSCLC), especially ALK (anaplastic lymphoma kinase) fusion-positive NSCLC.

Brigatinib/Brigatinib inhibits the activity of ALK fusion protein and blocks the activation of abnormal signaling pathways, thereby inhibiting the growth and spread of tumor cells. ALKfusion protein is an abnormal protein produced by the fusion of the ALK gene with other genes. It is more common in NSCLC patients. By inhibiting this specific molecular target, brigatinib can interfere with the survival and proliferation of tumor cells, thereby inhibiting tumor progression.

Brigatinib/Brigatinib is an oral drug and is supplied in tablet form. The generally recommended dose is to take it by mouth once daily with a meal. Specific dosage adjustments and treatment regimens should be individualized based on the patient's condition and physician's recommendations.

It needs to be emphasized that the use of Brigatinib/Brigatinib should be done under the guidance of a doctor and needs to be confirmed by ALK fusion-positive gene testing. Only after the patient's ALK fusion-positive status is clarified can it be determined whether the patient is suitable for brigatinib/brigatinib treatment.